ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenem, or piperacillintazobactam in a synergy time-kill analysis against 25 Pseudomonas aeruginosa strains with different resistance phenotypes. Each combination was synergistic against most isolates at 24 h, and antagonism was not observed. Combinations of ACHN-490 with cefepime, doripenem, imipenem, or piperacillin-tazobactam yielded synergies in >70% and >80% of strains at 6 and 12 h, respectively, and in >68% at 24 h.
Gram-negative nonfermentative rods such as Pseudomonas aeruginosa are being increasingly implicated in serious and sometimes life-threatening infections, particularly in the immunocompromised host (4, 8) . For some patients, multidrug resistance leaves colistin as the only therapeutic option, a drug that was removed from widespread use decades ago because of toxicity concerns (3, 5, 8) .
ACHN-490, a next-generation aminoglycoside, has been shown to be active against resistant Gram-negative rods, including P. aeruginosa (1, 2, 6, 7) . Combination antibiotic therapy is a potentially valuable option for the treatment of drug-resistant bacteria, e.g., P. aeruginosa (1, 5) . Therefore, a synergy timekill assay was used to test the activity of ACHN-490 with and without cefepime, imipenem, doripenem, or piperacillin-tazobactam (1, 2, 7).
Twenty-five P. aeruginosa strains, identified by standard methodology and isolated from clinical specimens (blood, urine, wounds, and respiratory tract) of different patients were studied. The strains were obtained from 1997 to 2008 from the United States (Hershey, PA, and Cleveland, OH) and Poland. The isolates were selected to include resistant phenotypes and did not represent a typical distribution of clinical P. aeruginosa isolates. The presence of genes encoding aminoglycoside-modifying enzymes (AMEs) was determined by PCR using primers and conditions described previously (1) .
ACHN-490 was supplied by Achaogen, Inc., South San Francisco, CA, while cefepime was from United States Pharmacopeia, Inc., Rockville, MD, doripenem was from Johnson & Johnson, Raritan, NJ, and imipenem and piperacillin-tazobactam was from Sigma, St. Louis, MO. MICs were determined by a modification of the broth macrodilution method, using a 24-h incubation. Kill kinetics of each drug alone were determined by incubating an initial inoculum of 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml with drug concentrations at the MIC and 2 dilutions above (2 and 4ϫ MIC) and 3 dilutions below the MIC (1/2, 1/4, and 1/8ϫ MIC). Viability counts were performed at 0, 3, 6, 12, and 24 h of incubation at 35°C in a shaking water bath by plating undiluted and 10-fold serially diluted samples (7). For synergy time-kill testing, ACHN-490 was combined with cefepime, imipenem, doripenem, or piperacillin-tazobactam and tested at 1 and 2 dilutions below the MIC of each drug. We used the following definitions: (i) synergy, a Ն2-log 10 decrease in CFU/ml between the combination and its most active constituent after 3, 6, 12, and 24 h, with the number of surviving organisms in the presence of the combination Ն2 log 10 CFU/ml below the starting inoculum; (ii) indifference, counts between a 2-log 10 CFU/ml decrease and a 2-log 10 CFU/ml increase between the combination and its most active constituent; (iii) antagonism, a Ն2-log 10 CFU/ml increase in counts between the combination and its most active constituent (7) . MIC data for each individual strain tested are listed in Table  1 . MIC ranges at 24 h for all strains tested were as follows: ACHN-490, 0.5 to 256 g/ml; cefepime, 1 to 256 g/ml; doripenem, 0.12 to 256 g/ml; imipenem, 0.25 to 512 g/ml; piperacillin-tazobactam, 2 to 4,096 g/ml. Genes encoding AMEs were found in 4 of the 25 strains: 3 had ant(2Љ)-Ia and 1 had aac(6Ј)-Ib. ACHN-490 MICs for these strains were equivalent to strains lacking AMEs. Table S1 in the supplemental material shows a summary of results of antimicrobial combinations with ACHN-490 studied in the time-kill synergy assays for each of the 25 P. aeruginosa strains tested. Subinhibitory combinations of ACHN-490 with cefepime, imipenem, doripenem, or piperacillin-tazobactam showed synergy against most P. aeruginosa strains, and no antagonism was observed ( Table 2 ). Figure 1 is a graphic Synergy  20  72  88  80  12  72  84  80  44  72  80  68  24  76  84  92  Indifference  80  28  12  20  88  28  16  20  56  28  20  32  76  24  16  8 Table 2 ).
The development of new antimicrobial agents is necessary based on the recent increase in multidrug-resistant P. aeruginosa strains (3, 8) . Combinations of ACHN-490 with any of the agents tested might improve the spectrum and therapeutic efficacy of these compounds against P. aeruginosa. Clinical studies are required to test the validity of this hypothesis.
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